ProPhase Labs Receivables 2010-2025 | PRPH

ProPhase Labs receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company

ProPhase Labs Receivables 2010-2025 | PRPH

ProPhase Labs receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$72B
Zoetis (ZTS)$69.3B
Takeda Pharmaceutical (TAK)$47.7B
Daiichi Sankyo, - (DSNKY)$45.3B
BeOne Medicines - (ONC)$33.5B
Sandoz Group AG (SDZNY)$27.7B
Summit Therapeutics (SMMT)$17.6B
Merck (MKKGY)$16.4B
Shionogi (SGIOY)$14.6B
Neurocrine Biosciences (NBIX)$13.8B
United Therapeutics (UTHR)$13.7B
IPSEN (IPSEY)$11.4B
Orion OYJ (ORINY)$11.2B
Madrigal Pharmaceuticals (MDGL)$9.7B
Eisai (ESAIY)$8.9B
Corcept Therapeutics (CORT)$7.3B
Stevanato Group S.p.A (STVN)$7B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.8B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.7B
Hypermarcas (HYPMY)$2.7B
Procaps Group, S.A (PROCF)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$2.1B